Black Diamond Therapeutic... (BDTX)
Black Diamond Therapeutics Inc. (BDTX) Stock Price, Analysis & Data
| Bid | 1.53 |
| Market Cap | 120.33M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -42.55M |
| Beta | 3.29 |
| EPS (ttm) | -0.75 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2.1 |
| P/B (ttm) | 1.26 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 5, 2026 |
| Ask | 2.59 |
| Volume | 641,576 |
| Avg. Volume (20D) | 1,664,509 |
| Open | 2.10 |
| Previous Close | 2.09 |
| Day's Range | 2.02 - 2.14 |
| 52-Week Range | 1.60 - 4.94 |
| Analyst | Strong Buy |
| Price Target | 10 (376.19%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BDTX
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 cl...
Financial Performance
In 2025, Black Diamond Therapeutics's revenue was 70M, an increase of undefined% compared to the previous year's 0. Earnings were 22.37M, a decrease of -132.1%.
Financial StatementsAnalyst Forecast
According to 7 analyst ratings, the average rating for BDTX stock is "Strong Buy". The 12-month stock price forecast is 10, which is upside of 376.19% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
